leucine has been researched along with Gangliosidoses, GM2 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belcher, G; Billington, I; Bremova-Ertl, T; Churchill, GC; Davis, W; Evans, W; Factor, M; Fields, T; Flint, S; Galione, A; Granzer, U; Greenfield, J; Karl, R; Kay, R; Lewi, D; Mathieson, T; Meyer, T; Pangonis, D; Patterson, M; Platt, FM; Strupp, M; Tsang, L; Verburg, C | 1 |
1 other study(ies) available for leucine and Gangliosidoses, GM2
| Article | Year |
|---|---|
A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia.
Topics: Ataxia Telangiectasia; Female; Gangliosidoses, GM2; Humans; Leucine; Male; Neurodegenerative Diseases; Quality of Life | 2021 |